Senseonics Holdings, Inc. (SENS) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Senseonics is a medical technology company focused on long-term, implantable continuous glucose monitoring (CGM) systems, primarily the Eversense E3 and the newly FDA-cleared Eversense 365. The company operates in a single segment and relies heavily on its commercialization partner, Ascensia Diabetes Care Holdings AG, for distribution.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $6,257 | $5,047 |
| Gross Profit | $1,505 | $335 |
| Gross Margin | 24.1% | 6.6% |
| Operating Loss | $(13,488) | $(18,232) |
| Net Loss | $(14,259) | $(18,877) |
| Cash & Cash Equivalents | $39,311 | $74,597 |
| Short-term Investments | $24,926 | $0 |
| Total Liquidity (Cash + Investments) | $64,237 | $74,597 |
| Long-term Debt (Net) | $34,961 | $34,703 |
| Accumulated Deficit | $(962,133) | $(888,135) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 24% ($1.2 million) year-over-year, driven by US sales growth in the consignment program and demand for the 365-day product.
- Margin Expansion: Gross margin improved significantly from 6.6% to 24.1%. This was primarily due to the capitalization of manufacturing costs for the Eversense 365 product following FDA approval (previously expensed as R&D) and favorable margins on the new product.
- Expense Reduction: Operating loss narrowed by $4.7 million. R&D expenses decreased by $3.1 million due to the completion of Eversense 365 clinical trials and headcount reductions. SG&A expenses decreased by $0.4 million.
- Debt Repayment: The company fully repaid the remaining $20.4 million principal of its 2025 Convertible Notes in January 2025, eliminating this liability from the balance sheet.
- Investment Activity: The company purchased $24.9 million in marketable securities during the quarter, shifting cash into short-term investments.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has determined that substantial doubt exists regarding the company's ability to continue as a going concern for the next 12 months. Current cash and marketable securities ($64.2 million) are not expected to be sufficient to fund operations and meet debt covenants through Q1 2026 without additional financing.
- Commercialization: The company is transitioning coverage policies for the Eversense 365 system with payors. A new collaboration with Sequel Med Tech was announced in April 2025 to integrate Eversense 365 with an automated insulin delivery system, with a target launch in Q3 2025.
- Customer Concentration: 71% of Q1 2025 revenue was derived from a single customer, Ascensia. The company's success remains heavily dependent on Ascensia's commercial execution.
- Legal Proceedings: A patent infringement lawsuit filed by Cellspin Soft, Inc. in May 2024 has been stayed pending the resolution of Inter Partes Review proceedings at the USPTO.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and terms of any new financing required to bridge the gap before Q1 2026, given the explicit "substantial doubt" disclosure.
- Debt Covenants: Review the Loan and Security Agreement covenants, specifically the minimum cash requirements (30% of funded amounts) and performance milestones, to assess the risk of default.
- Revenue Sustainability: Assess the durability of the gross margin improvement, noting that it was partially driven by the one-time accounting shift of capitalizing inventory costs for the Eversense 365.
- Ascensia Partnership: Monitor the status of the Commercialization Agreement and Ascensia's ability to meet spending and revenue targets, as failure could lead to termination or conversion to non-exclusive rights.
- Patent Litigation: Track the outcome of the Inter Partes Review regarding the Cellspin Soft patent challenge, as a loss could impact future product sales.